
Neurological biomarkers market size was valued at $5.4 billion in 2021, and is estimated to reach $18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimerโs and Parkinsonโs is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimerโs and Parkinsonโs.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the neurological biomarkers market forecast, future estimations and neurological biomarkers market trends to elucidate the imminent investment pockets.
- It presents a quantitative analysis of the market from 2021 to 2031 to enable stakeholders to capitalize on the prevailing neurological biomarkers market opportunity.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the neurological biomarkers industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the neurological biomarkers industry.
Market Size By 2031:
- USD 18.9 billion
Growth Rate:
- CAGR of 13.6%
Forecast period:
- 2021 - 2031
By Type:
- Genomic
- Proteomic
- Metabolomic
- Others
By Application:
- Parkinson's Disease
- Alzheimer's Disease
- Multiple Sclerosis
By Region:
- North America (U.S., Canada)
- Europe (Germany, France, UK, Rest Of Europe)
- Asia-Pacific (Japan, China, India, Rest Of Asia-Pacific)
- LAMEA (Brazil, Saudi Arabia, Rest Of LAMEA)
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Bio-Rad Laboratories, Inc.
- Quanterix
- merck kgaa
- darmstadt
- germany
- bioMรฉrieux
- F. HOFFMANN-LA ROCHE LTD.
- MYRIAD RBM (MYRIAD GENETICS, INC.)
- PERKINELMER INC.
- Thermo Fisher Scientific, Inc.
- Neurobio, shimadzu corporation
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/3555
The neurological biomarkers market can be segmented in various ways based on different factors. Here are some common segmentation approaches for the neurological biomarkers market:
Biomarker Type:
a. Genomic Biomarkers: This segment includes biomarkers derived from genes and their expression patterns, such as single nucleotide polymorphisms (SNPs) and gene expression profiles.
b. Proteomic Biomarkers: This segment includes biomarkers derived from proteins, such as protein expression levels, protein modifications, and protein-protein interactions.
c. Imaging Biomarkers: This segment includes biomarkers obtained through various imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans.
d. Metabolomic Biomarkers: This segment includes biomarkers derived from metabolites, such as small molecules and metabolic pathways.
e. Others: This segment may include other types of biomarkers, such as epigenetic biomarkers or microRNA biomarkers.
Disease Type:
a. Alzheimer's Disease: This segment focuses on biomarkers associated with Alzheimer's disease, such as amyloid beta and tau proteins.
b. Parkinson's Disease: This segment focuses on biomarkers associated with Parkinson's disease, such as alpha-synuclein and dopamine levels.
c. Multiple Sclerosis: This segment focuses on biomarkers associated with multiple sclerosis, such as myelin basic protein and neurofilament light chain.
d. Stroke: This segment focuses on biomarkers associated with stroke, such as brain-derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP).
e. Other Neurological Disorders: This segment may include biomarkers associated with other neurological disorders, such as epilepsy, Huntington's disease, and traumatic brain injury.
End User:
a. Hospitals and Clinics: This segment includes biomarker testing conducted in hospitals and clinics by healthcare professionals.
b. Research Institutes and Academic Centers: This segment focuses on biomarker research conducted in academic and research settings.
c. Diagnostic Laboratories: This segment includes biomarker testing conducted in specialized diagnostic laboratories.
d. Pharmaceutical and Biotechnology Companies: This segment focuses on biomarker discovery and development carried out by pharmaceutical and biotech companies.
Region:
a. North America: This segment includes the United States and Canada.
b. Europe: This segment includes countries in Europe, such as the United Kingdom, Germany, France, and Italy.
c. Asia-Pacific: This segment includes countries in the Asia-Pacific region, such as China, Japan, India, and Australia.
d. Latin America: This segment includes countries in Latin America, such as Brazil and Mexico.
e. Middle East and Africa: This segment includes countries in the Middle East and Africa region.
๐๐ฎ๐ฒ ๐๐จ๐ฐ: https://www.alliedmarketresearch.com/checkout-final/9f0e3bf3e66f160fbacb254909054633
๐๐๐๐๐๐- ๐ ๐๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐๐ข๐๐ซ๐๐ซ๐ฒ (๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐จ๐ง-๐๐๐ฆ๐๐ง๐, ๐ฌ๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐ฉ๐ซ๐ข๐๐ข๐ง๐ ๐ฆ๐จ๐๐๐ฅ) ๐๐๐๐๐ซ๐๐ ๐๐ฒ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/purchase-enquiry/3555
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Contact Us:
David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
Web: https://www.alliedmarketresearch.com